Ashton Thomas Securities LLC Buys New Stake in IQVIA Holdings Inc. (NYSE:IQV)

Ashton Thomas Securities LLC purchased a new stake in IQVIA Holdings Inc. (NYSE:IQV) in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor purchased 241 shares of the medical research company’s stock, valued at approximately $57,000.

Several other hedge funds also recently added to or reduced their stakes in IQV. PGGM Investments raised its holdings in shares of IQVIA by 55.8% during the 2nd quarter. PGGM Investments now owns 12,073 shares of the medical research company’s stock valued at $2,553,000 after buying an additional 4,326 shares during the period. Quadrature Capital Ltd purchased a new stake in shares of IQVIA during the first quarter valued at approximately $3,365,000. Raymond James & Associates boosted its stake in shares of IQVIA by 0.7% in the second quarter. Raymond James & Associates now owns 800,374 shares of the medical research company’s stock valued at $169,231,000 after purchasing an additional 5,417 shares during the period. UniSuper Management Pty Ltd grew its holdings in IQVIA by 253.0% during the 1st quarter. UniSuper Management Pty Ltd now owns 6,029 shares of the medical research company’s stock valued at $1,525,000 after purchasing an additional 4,321 shares in the last quarter. Finally, Sei Investments Co. increased its stake in IQVIA by 4.8% during the 1st quarter. Sei Investments Co. now owns 57,887 shares of the medical research company’s stock worth $14,638,000 after buying an additional 2,638 shares during the period. 89.62% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, insider Eric Sherbet sold 1,300 shares of the company’s stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the transaction, the insider now directly owns 19,536 shares in the company, valued at $4,812,302.88. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 1.60% of the company’s stock.

IQVIA Stock Performance

Shares of IQV stock opened at $211.49 on Thursday. The company has a market cap of $38.39 billion, a P/E ratio of 27.75, a PEG ratio of 2.20 and a beta of 1.51. The business has a 50 day moving average of $229.61 and a two-hundred day moving average of $228.89. IQVIA Holdings Inc. has a 52 week low of $197.37 and a 52 week high of $261.73. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on IQV shares. Jefferies Financial Group downgraded IQVIA from a “buy” rating to a “hold” rating and lowered their target price for the company from $266.00 to $242.00 in a research note on Wednesday, July 24th. Evercore ISI lowered their price objective on IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. StockNews.com lowered IQVIA from a “buy” rating to a “hold” rating in a research report on Friday, November 8th. TD Cowen decreased their price target on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Finally, Morgan Stanley reduced their price objective on shares of IQVIA from $280.00 to $265.00 and set an “overweight” rating on the stock in a research note on Monday, November 4th. Five analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $259.13.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.